VedaBio Launches with $40+ Million Toward a CRISPR Molecular Detection Platform

Today, VedaBio, co-founded by Ganguli, emerged from stealth mode and unveiled its Cascade™ molecular detection platform. Ganguli, who is CEO, said that this CRISPR-based technology has the best accuracy in its class, can detect molecules at room temperature, and gives results almost instantly without the need for target amplification. This is how Veda, which means “the creation of knowledge” in Sanskrit, was able to raise more than $40 million and get support from OMX Ventures, the company’s lead investor.